Semax vs Telmisartan
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Semax and Telmisartan can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Semax Telmisartan
Weight 813.93 Da 514.62 Da
Half-life 0.5-2 hours ~24 hours
Chain 7 amino acids —
Type ACTH(4-10) synthetic analog Benzimidazole derivative (C33H30N4O2)
Key Benefits
Semax
01 Rapid brain delivery via intranasal route
02 Rapidly increases BDNF levels
03 Extensive clinical research in Russia
04 Easy self-administration
05 Modulates dopamine and serotonin systems
06 Neuroprotective effects
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Dosing Protocols
Semax
300-600mcg per dose (up to 1000mcg for intensive use) / 1-2x daily (morning recommended for cognitive boost)
Research protocol 500-750mcg 1x daily
Intensive protocol 750-1000mcg 1-2x daily
Telmisartan
20-80 mg/day / Once daily
Side Effects
Semax
Mild nasal discomfort (nasal route)
Possible nasal sensation upon administration
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Pregnancy or breastfeeding
Known peptide allergies
Do not exceed 4-week continuous use without medical supervision
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Semax Telmisartan
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest 2025 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.